# UK Patent Application (19) GB

(11) 2

(43) Application published 2 Oct 1985

1114731375

(21) Application No 8503900

(22) Date of filing 15 Feb 1985

(30) Priority data (31) 840655

(71) Applicant

(32) 17 Feb 1984

(33) FI

(52) Domestic classification G1B 114 211 315 412 418 513 514 515 516 BT C3H 606 621 B7

(51) INT CL4

G01N 33/53

U1S 1337 C3H G1B (56) Documents cited WO A1 8301459 = EP7 9137

Orion-Yhtyma OY (Finland), P O Box 65, 02101 Espoo, Finland

(72) Inventors Airi Marjatta Palva Tuula Marjut Ranki Hans Erik Soderlund

(74) Agent and/or Address for Service JY & G W Johnson, Furnival House, 14-18 High Holborn, London WC1V 6DE

(58) Field of search

G<sub>1B</sub> СЗН


## (54) Improved nucleic acid reagents and methods for their preparation


(57) The invention is related to improved nucleic acid reagents comprising arrays of nucleic acid fragments and combinations of such fragments. The preparation of such fragments by recombinant DNA techniques and their use in hybridization methods is also described.

The improved nucleic acid reagents comprise two series, one labeled and one affixed to a solid carrier of at least two but preferably more arrays of alternating nucleic acid fragments, which are sufficiently homologous to sequences in the nucleic acid to be identified. Nucleic acid fragments belonging to different series must not be homologous to each other.

#### BEST AVAILABLE COPY


#### Hin. 1










## Hin. 3




#### Hig. 4










Hig. T







Hig. 8











Hig. 9






## Hin. 111




# Hin.11




717

Hing. 12



### Hin.13



10

15

20

25

30

35

40

45

50

55

60

# Improved nucleic acid reagents and methods for their preparation

5 The invention relates to improved nucleic acid reagents comprising an array of nucleic acid fragments and to combinations of such improved reagents. The invention also relates to methods for the preparation of nucleic acid reagents comprised of an array of clones, and combinations of such nucleic acid reagents, by recombinant-DNA techniques, and to their use for the identification of nucleic acids by hybridization methods. 10

Various hybridization methods have commonly been used for the identification and study of nucleic acids. Some examples are the direct hybridization methods, in which the sample containing the nucleic acid to be identified is either in a solution (Brautigam et al., J.Clin.Microbiol., 1980, 12, 226-234 and the British Patent Publication No. 2,019,408) or affixed to a solid carrier (US-Patent Nos 4,139,346, 4,302,204, 4,358,535, 4,395,486, the British 15 Patent Publications Nos. 2,034,323, 2,095,833, the European Patent Publications Nos

62,286, 62,237 and 61,740), and is detected by using one labeled nucleic acid reagent which

Other known hybridization methods include the two-step sandwich hybridization method presented by Dunn and Hassell in Cell, 12, 23-36, 1977, and the one-step sandwich 20 hybridization methods presented in the European Patent Publication No. 79,139. For the identification of the nucleic acids by the sandwich methods two separate nucleic acid reagents are needed to detect the nucleic acids present in the sample solution. One of these reagents is affixed to a solid carrier and the other is labeled.

Nucleic acid reagents, both those affixed to a solid carrier and those which are labeled, are 25 characterized in that their base sequence is complementary, or nearly complementary, to the nucleic acid to be identified, i.e. homologous. The nucleic acid reagents used are either natural nucleic acids as such or as fragments of them. The fragments are produced, for example, by using restriction enzymes. Nucleic acid reagents have also been prepared synthetically or by recombinant-DNA techniques. Natural plasmids (US-Patent No. 4,358,535), nucleic acids from

30 bacteriophages (US-Patent No. 4,543,535), ribosomal RNA and messenger RNA (US-Patent No. 4,302,204), or nucleic acid from different viruses (Stålhandske et al., Curr. Top. Microbiol. Virol. 104, 1983) have been used as the nucleic acid reagents. The whole virus genome has been used for identifying, for example, parts belonging to the different viruses in the messenger RNA of a hybrid virus (Dunn and Hassell, Cell, 12, 23-36, 1977). Nucleic acid reagents have

35 also been prepared by using recombinant-DNA techniques (US-Patents Nos 4,395,486 and 4,359,535, the European Patent Application No. 79,139 and the British Patent Publication No. 2,034,323 and the European Patent Application No. 62,286). Nucleic acid reagents produced by recombinant-DNA techniques have been used either in such a way that the replicated defined DNA fragment has been purified out from the DNA of the vector, or as recombinant-DNA

40 molecules linked to different vectors. The previously used nucleic acid reagents produced by recombinant-DNA techniques are made up of one continuous identifying nucleic acid fragment

We have developed new, more sensitive nucleic acid reagents, comprising at least two series of alternating arrays of nucleic acid fragments prepared from either one or several segments 45 homologous to the nucleic acid to be identified.

Nucleic acid reagents which comprise such arrays of nucleic acid fragments are in sandwich hybridization tests at least twice as sensitive as the previously used nucleic acid reagents. By using the nucleic acid reagents according to the invention, or their combinations, it is possible to identify smaller amounts of nucleic acids than previously, and they are especially well applicable 50 for sandwich hybridization methods.

The higher sensitivity of the nucleic acid reagents according to the invention in sandwich hybridization methods is in part based on the fact that the use of several probes increases the quantity of labeled hybrids on the solid carrier. There may be labeled vector-derived nucleic acid along with every hybridizing probe (Figs. 1 and 2). In Figs. 1 and 2, v represents vector-derived 55 DNA, x the nucleic acid to be identified, b the labeled probe, a the identifying nucleic acid

reagent affixed to the solid carried, and F the filter. When several probes are used, the quantity of labeled, vector-derived nucleic acid parts increases, and more label is bound to the hybrids being formed. The hybrids are thus more easily detectable.

When the array of nucleic acid fragments according to the invention are used in sandwich 60 hybridization methods, at least two, or as shown in Fig. 1, three, identifying nucleic acid fragments are affixed to the solid carrier. In this case the different areas of the nucleic acid strand x to be detected may hybridize to the nucleic acid fragments affixed to the solid carrier, for example a<sub>1</sub>, a<sub>2</sub>, and a<sub>3</sub>, at one or several points, depending on the degree of reaction. When the reaction reaches its final stage, a situation according to 5

65 the same!

15

20

25

30

35

40

45

50

55

65

5	Fig. 1, hybridize. At this time the distance of the vector-derived nucleic acid parts from the hybridization joining point (1) d creases (Fig. 1), and the hybrid is more stable than the hybrid formed by one reagent pair (prior art) shown in Fig. 2, this hybrid being of the same size as the total area of the array of nucleic acid fragments. The vector-derived parts of a hybrid formed from one reagent pair are easily broken by, for example, mechanical strain, such as shaking. In such a case the label already bound to the hybrid escapes.
	Since the improved nucleic acid reagents according to the invention are more sensitive than previously used nucleic acid reagents, they are suitable for demonstrating chromosomal rearrangements and hereditary diseases.
10	Our invention relates to nucleic acid reagents comprising an array of nucleic acid fragments, their combinations, their preparation, and their use for the detection of nucleic acids in hybridization methods.
	The characteristics of the invention are shown in the distinguishing features of the claims, and

the invention is described in greater detail in the following description and in the acompanying 15 drawings, in which

Figure 1 shows an array of sandwich hybrids,

Figure 2 depicts a sandwich hybrid of the prior art,

Figure 3 shows the sites of two alternating series of nucleic acid fragments in a nucleic acid which has been selected for the preparation of an array of nucleic acid reagents according to the 20 invention.

Figure 4 shows the corresponding sites of three alternating series of arrays of nucleic acid

Figure 5 shows an array of nucleic acid fragments according to Fig. 3 separate (a), joined together (b) and both separate and joined together (c),

Figure 6 shows an array of sandwich hybrids,

Figure 6a shows an array of sandwich hybrids which is formed when separate fragments are

Figure 6b shows an array of sandwich hybrid which is formed when joined b-fragments are used.

Figure 6c shows an array of sandwich hybrids which is formed when bothseparate and joined 30 b-fragments are used.

Figure 7 shows an array of nucleic acid reagents which identify different nucleic acids, Figure 8 shows an array of sandwich hybrids which are formed when the array of nucleic acid reagents according to Fig. 7, identifying different nucleic acids, are used.

Figure 9 shows an array of hybrids formed by a direct hybridization method, Figure 10 shows the recombinant plasmid pKTH1220,

Figure 11 shows an array of sandwich hybrids which is formed when an array of nucleic acid fragments prepared from the recombinant plasmid pKTH1220 are used,

Figure 12 shows the recombinant plasmid pKTH1271,

Figure 13 shows an array of sandwich hybrids which is formed when arrays of nucleic acid fragments prepared from the recombinant plasmid pKTH1271 are used.

Our invention relates to nucleic acid reagents composed of an array of nucleic acid fragments. These arrays of nucleic acid reagents comprise at least two, but preferably several, alternating nucleic acid fragments, up to 20 fragments, which are derived from one or several nucleic acids 45 sufficiently homologous to the nucleic acid which is to be identified. Thereby there are obtained at least two series of alternating arrays of nucleic acid fragments, which must not be

homologous to one another. The arrays of nucleic acid reagents can be prepared synthetically. In this case the fragments

from the two alternating series of arrays of nucleic acid fragments, must not be homologous to 50 each other. But they must be sufficiently homologous to alternating sites in the nucleic acids to be identified. These fragments can easily be prepared by fully automatic machines after characterization of the nucleic acid sequence of the nucleic acid to be identified.

The nucleic acid reagents according to the invention are composed of separate, or joined, or both separate and joined array of nucleic acid fragments.

The arrays of nucleic acid fragments.

The arrays of nucleic acid fragments may be joined to a vector, contain parts of vectors, or be totally devoid of vector parts.

The nucleic acid fragments used have a minimum length of 15 nucleotides. There is no actual upper limit for length, but it is advantageous to use fragments having a length of 20-5000 nucleotides. The nucleic acid fragments according to the invention are derived either from the 60 genome to be identified or from one part of the genome, for example from a relatively large clone representing a certain part of the genome. The arrays of nucleic acid fragments according to the invention can thus be prepared from several independent genome areas which are not directly adjacent. The arrays of nucleic acid fragments thus prepared are combined and used for the same reagent. The arrays of nucleic acid fragments can also be isolated from a DNA which

65 is not identical to the nucleic acid to be identified but sufficiently homologous, so that a stable

0

5

3

5

15

20

25

30

35

40

45

50

55

60

The reagents are isolated in such a way that at least two series of alternating nucleic acid fragments, a<sub>1</sub>, a<sub>2</sub>, a<sub>3</sub>, etc., and b<sub>1</sub>, b<sub>2</sub>, b<sub>3</sub>, etc., are obtained. The nucleic acid fragments adjacent to one another. The nucleic acid fragments belonging to the series a<sub>1</sub>, a<sub>2</sub>, a<sub>3</sub>, etc. are composed of fragments situated close to but not also composed of nucleic acid fragments situated close to but not adjacent to one another. The nucleic acid fragments belonging to the series a<sub>1</sub>, a<sub>2</sub>, a<sub>3</sub>, etc. and those belonging to the series b<sub>1</sub>, b<sub>2</sub>, b<sub>3</sub>, etc. must not be homologous to each other. It is preferable that the nucleic acids isolated in such a way that every second fragment belonging to the series a<sub>1</sub>, a<sub>2</sub>, a<sub>3</sub>, etc. and those belonging to the a-series and every second to fragments sufficiently homologous to the nucleic acid to be identified. It is, of course, possible acid, as shown in Fig. 4. It is preferable that the alternating two nucleic acid reagents follow one

The nucleic acid fragment series described in the invention.

The nucleic acid fragment series described above can be used either as separate fragments a<sub>1</sub>, a<sub>2</sub>, a<sub>3</sub>, etc., and b<sub>1</sub>, b<sub>2</sub>, b<sub>c</sub>, etc. (Fig. 5a) or joined together into longer strands a<sub>1</sub>-a<sub>2</sub>-a<sub>3</sub>, etc., and b<sub>1</sub>-b<sub>2</sub>-b<sub>3</sub>, etc. (Fig. 5b). It is, of course, possible to prepare all kinds of intermediate forms together, and in the b-series, for example, b<sub>1</sub>-b<sub>2</sub> are joined together and b<sub>3</sub> is separate, etc., as

Fig. 6 depicts various arrays of sandwich hybrids. Fig. 6a shows an array of sandwich hybrids in which the arrays of nucleic acid fragments are separate. Fig. 6b shows an array of hybrids in which the labeled array of nucleic acid fragments are joined together. Fig. 6c depicts a case in which an array of sandwich hybrids is formed from both joined and separate labeled arrays of nucleic acid fragments. In Fig. 6, x represents the nucleic acid to be identified; b<sub>1</sub>, b<sub>2</sub>, and b<sub>1</sub> to a solid carrier.

Nucleic acid fragments which belong to the b-series can, for example, be labeled in such a way that a labeled nucleic acid reagent is obtained, i.e. the probe B. The nucleic acid reagents which belong to the a-series can be affixed to a solid carrier in such a way that a nucleic acid reagent A bound to a solid carrier is obtained. It is, of course, alternatively possible to prepare a carrier.

Such nucleic acid pairs A and B, or B and A, labeled and respectively affixed to a solid carrier can be prepared for several different nucleic acids to be identified. They can be combined into suitable nucleic acid reagent combinations, which are composed of different nucleic acid reagent containing arrays of nucleic acid fragments which identify different nucleic acids can also be nucleic acid fragments (a<sub>1</sub>-a<sub>2</sub>-a<sub>3</sub>), -(a<sub>1</sub>-a<sub>2</sub>-a<sub>3</sub>), -(a<sub>1</sub>-a<sub>2</sub>-a<sub>3</sub>), as shown in Fig. 7, in which a<sub>1</sub>, a<sub>2</sub>, arrays of nucleic acid fragments A<sub>2</sub> which identify nucleic acid x; a<sub>1</sub>, a<sub>2</sub>, and a<sub>3</sub>, are arrays of nucleic acid fragments A<sub>3</sub> which identify nucleic acid x; a<sub>1</sub>, a<sub>2</sub>, and a<sub>3</sub>, are arrays of nucleic acid fragments A<sub>3</sub> which identify nucleic acid y; a<sub>1</sub>, a<sub>2</sub>, and a<sub>3</sub>, are arrays of nucleic acid fragments A<sub>3</sub> which identify nucleic acid y; a<sub>1</sub>, a<sub>2</sub>, and a<sub>3</sub>, are arrays of nucleic acid fragments A<sub>3</sub> which identify nucleic acid y; a<sub>1</sub>, a<sub>2</sub>, and a<sub>3</sub>, are arrays of nucleic acid fragments A<sub>3</sub> which identify nucleic acid y; a<sub>1</sub>, a<sub>2</sub>, and a<sub>3</sub>, are arrays of nucleic acid fragments Can, of course, also be used as separate fragments.

as suitable mixtures.

The arrays of sandwich hybrids according to Fig. 8 are obtained by using the reagents shown in Fig. 7. If simultaneous identification of several different nucleic acids is desired, it is, of identifying the nucleic acid x, Fig. 8b a solid carrier identifying the nucleic acid x, Fig. 8b a solid carrier identifying the nucleic acid y, and Fig. 8c a solid carrier identifying the nucleic acid y, and Fig. 8c a nucleic acid fragments affixed to a solid carrier and identifying the nucleic acid x; b<sub>1</sub>, and b<sub>2</sub>, are arrays of nucleic acid fragments affixed to a solid carrier and identifying the nucleic acid y; and b<sub>1</sub>, are b<sub>1</sub>, and b<sub>2</sub>, are arrays of nucleic acid fragments affixed to a solid carrier and identifying the nucleic acid y; and b<sub>1</sub>, and b<sub>2</sub>, are arrays of nucleic acid fragments affixed to a solid carrier and identifying the nucleic acid y; and nucleic acid z; and x, y and z are the nucleic acids to be identified. F<sub>1</sub>, F<sub>2</sub> and F<sub>3</sub> are the respective solid carriers or filters, A<sub>1</sub>-A<sub>2</sub>-A<sub>3</sub> is a probe which identifies all the three nucleic acids

simultaneously, if separate solid carriers are used.

The above-described nucleic acid fragment series, reagents and reagent combinations can be prepared by recombinant-DNA techniques known per se. A number of nucleic acid fragments of different lengths are generated, by using restriction enzymes, from the nucleic acid to be

known, it is possible to select from the genome the suitable adjacent fragments, generated by using restriction enzymes, and the fragments are isolated and amplified by using recombinant DNA techniques.

When an unknown genome is involved, an intermediate stage can be used in the preparation of the reagents, in such a way that a relatively large restriction fragment is cloned, this fragment is mapped, and the arrays of nucleic acid fragments series  $a_1$ ,  $a_2$ ,  $a_3$ , etc., and  $b_1$ ,  $b_2$ ,  $b_3$  etc., are produced on the basis of the information thus obtained.

It is, of course, possible to use combinations of the above methods and to use several large separate cloned restriction fragments as starting material, and to prepare several separate series, which are combined to form suitable combinations.

It is advantageous to prepare the nucleic acid fragment series  $a_1$ ,  $a_2$ ,  $a_3$ , etc., and  $b_1$ ,  $b_2$ ,  $b_3$ , etc., according to the invention by using recombinant-DNA techniques in such a way that the series a is cloned into one vector, for example into the plasmid pBR322, and whereas the series b is cloned into another suitable vector, which does not have sequences in common with the previous vector. The bacteriophase M13 is an example of such a second advantageous vector. The fragments belonging to the series a can be joined to one another, and the joined series can be cloned into one vector. For example,  $a_1-a_2$ , joined together, can be cloned as a continuous insert into the same pBR322 vector. In a corresponding manner it is possible to prepare a reagent series  $b_1-b_2$ . In the cloning it is preferred to use vectors to which very large inserts of foreign DNA can be joined. For example, lambdaphage and cosmid vectors are suitable for this purpose.

Thus, two reagent pairs comprising arrays of nucleic acid fragments are needed in the sandwich hybridization method according to the invention, a reagent labeled with the label substance to be identified, i.e. a probe, and a so-called filter reagent affixed to a solid carrier.

Most commonly, radioactive isotopes are used for labeling the probes. For example in the British Patent Publication No. 2,034,323, the US-Patents Nos 4,358,535 and 4,302,204 the following isotopes are used: <sup>32</sup>P, <sup>125</sup>I, <sup>131</sup>I and <sup>3</sup>H. In the European Patent Publication No. 79,139, the isotope <sup>125</sup>I is used. Nucleic acid probes have also been modified in different ways and labeled with, e.g. fluorescent labels (French Patent Publication No. 2,518,755). Also enzymatic or enzymatically measureable labels are used (the British Patent Publication No. 2,019,408, the European Patent Publication No. 63,879 and the French Patent Publication No.

2,019,408, the European Patent Publication No. 63,879 and the French Patent Publication No. 2,519,005). The European Patent Publications Nos 70,685 and 70,687 describe a light-emitting label and labeling method, and the French Patent Publication No. 2,518,755 describes an immunologically measurable label. The lanthanide chelates described in US-Patent No. 35,4,374,120, especially europium, can be used as label substances. Also the highin avidio label.

35 4,374,120, especially europium, can be used as label substances. Also the biotin-avidin label substance described by Leary et al. (PNAS 80, 4045-4049, 1983) is suitable as a label. A few examples of labels which can be used for the labeling of nucleic acid reagents according to the invention are mentioned above, but it is evident that there will be developed new, improved label substances which are also suitable for the labeling of arrays of nucleic acid fragments 40 according to the invention.

The carriers suitable for filter reagents include various nitrocellulose filters (US-Patent No. 4,358,535 and the British Patent Publication No. 2,095,833). The DDR-Patent Publication No. 148,955 describes a method of binding nucleic acids chemically to the carrier (paper). US-Patents Nos 4,359,535 and 4,302,204 describe chemically modified papers which can be

US-Patents Nos 4,359,535 and 4,302,204 describe chemically modified papers which can be used as solid carriers. Other alternatives include nylon membranes and modified nitrocellulose filters. But it is evident that there will be developed new materials which will be even more suitable for use as solid carriers according to the invention. It is, of course, possible to use also other solid carriers, such as various chromatography matrices such as triazine- or epoxy-activated cellulose, latex, etc. In principle, there are no other limitations to the selection of the solid carrier than those to be described below. It has to be possible to affix nucleic acid in a single-stranded

50 than those to be described below. It has to be possible to affix nucleic acid in a single-stranded form to the solid carrier so that these single-stranded nucleic acids can hybridize with the complementary nucleic acid. The solid carrier must also be easy to remove from the hybridization solution, or the hybridization solution must be easy to remove from the solid carrier. Also, the probe must not adhere to the carrier material itself so that it cannot be washed off.

The above-described combinations of the arrays of nucleic acid reagent pairs A and B, or B and A, labeled and affixed to a solid carrier respectively, and from such nucleic acid pairs made for the identification of different nucleic acids it is possible to assemble a combination A, and B, A, and B, A, and B,

These combinations can be used for the simultaneous identification of the nucleic acids, x, y and z by sandwich hybridization methods.

The sample is treated in such a way that the nucleic acids are released into the hybridization solution, and they are rendered single-stranded. The hybridization is carried out in a hybridization solution, to which both the nucleic acid reagents affixed to a solid carrier and the labeled ones are added. When hybridization has taken place, the filters are lifted from the hybridization

15

10

20

25

30

35

40

45

0

55

60

65

10

15

20

25

30

35

40

45

50

55

60

Several different mixtures can be used as the hybridization solution; the alternatives presented examples. It is, of course, also possible to use other hybridization mixtures. The hybridization of 65°C. Sufficient hybridization may occur in a very short period, but it is advantageous to use hybridization periods of, for example, 12–20 hours.

The two-step sandwich hybridization method is carried out in principle in the same manner, but in this case the nucleic acid reagent affixed to a solid carrier is first added to the hybridization solution. When the hybridization has taken place, the solid carrier is washed and a second hybridization is carried out in which the labeled nucleic acid reagent is present.

The above-described labeled nucleic acid reagents or reagent combination A, A, A, etc., and nucleic acid sample in a solution must be divided for each nucleic acid x, y and z to be identified or, if the sample is affixed to a solid carrier, a separate sample affixed to a carrier must be prepared for each sample. The formed array of hybrids (Fig. 9) is detected by methods known per se. In Figs. 9, F represents the solid carrier, i.e. the filter, x the nucleic acid to be identified, and v the vector-derived parts. The labeled probes used are a<sub>1</sub>, a<sub>2</sub> and a<sub>3</sub> (Fig. 9a), b<sub>1</sub> and b<sub>2</sub> (Fig. 9b), and a<sub>1</sub>, b<sub>1</sub>, a<sub>2</sub>, b<sub>2</sub>; a<sub>3</sub> (Fig. 9c).

As already described above, various combinations of nucleic acid reagents can be made up from the arrays of nucleic acid fragments according to the invention. It is possible by using acid fragments homologous to the different nucleic acids simultaneously. Arrays of nucleic separate fragments in the mixtures or joined together in such a manner that one probe identifying several different nucleic acids is obtained. Nucleic acid reagents affixed to a solid carrier must, of course, be kept separate in order for the identification to be successful.

Hybridization using arrays of nucleic acid fragments can be used for identifying various human, animal and plant pathogenic microorganisms. By the method it is possible to identify cause food poisonings. The method is suitable for the identification of contaminants present in Since the conductor and enteroviruses.

Since the sandwich hybridization test using arrays of nucleic acid fragments is a quantitative method, it is applicable to, for example, the detection and measurement of gene amplification. This characteristic is significant in, for example, the detection and treatment of cancer. The formation of a stable array of hybrids requires that the homologous sequences of the probe reagent and the filter reagent are located within a moderate, preferably less than 5 kilobase (kb), these two areas do occur, the change is clearly a treatment of the distance between

these two areas do occur, the change is cleary observable by this method. Therefore the method is also suitable for the detection of changed mRNA, chromosomal rearrangements, the rearrangement of immunoglobulin genes for expression, and hereditary diseases. It is thus possible to construct various reagent combinations from the arrays of nucleic acid fragments. For example, for the identification of the causative agents of venereal diseases it is possible to prepare kits which include a probe which contains arrays of nucleic acid fragments which identify gonorrhea, syphilis, herpes and chlamydiae. The identification is in this case possible by using separate filters for gonorrhea, syphilis, herpes and chlamydiae.

The invention relates particular to arrays of nucleic acid fragments comprising the recombinant plasmids pKTH1220 and pKTH1271. The recombinant plasmid pKTH1220 comprises, in the plasmid vector pBR322, DNA of Chlamydia trachomatis L2 which is specific to the Chlamydiae. This recombinant plasmid is cloned into the host Escherichia coli K12 HB101. The recombinant plasmid 1271 comprises, in the plasmid vector pBR325, DNA from the cytomegalovirus AD169. This recombinant plasmid is cloned into host Escherichia coli K12 HB 101. The hosts containing the recombinant plasmids pKTH1220 and pKTH1271 have been deposited at

the culture collection Deutsche Sammlung von Mikroorganismen (DSM), Griesebachstrasse 8. plasmid pKTH1220 is DSM2825 and the number of the deposit containing the recombinant plasmid pKTH1271 is DMS2826. The deposits will be freely available once the patent

15

20

25

30

35

50

55

60

65

not, however, be understood as limiting the protective scope of the invention. The structure of the nucleic acid (DNA and RNA) is similar whether the question is of a nucleic acid derived from a eucaryotic or a procaryotic cell. For this reason the principles presented in the examples are equally well applicable to the nucleic acids of animals (man included), plants and microbes or viruses. Thus the reagents according to the invention can be used to detect the nucleic acids of man, animals, plants, microbes and viruses. The arrays of nucleic acid fragments can be prepared synthetically, too. The sequence of nucleic acids to be identified can be characterized and homologous arrays of fragments prepared by automatic nucleic acid preparation machines.

10 Example 1

(a) Arrays of nucleic acid reagents from Chlamydia trachomatis and their preparation DNA fragments suitable for the diagnostics of the Chlamydia trachomatis group were prepared from the DNA of Chlamydia trachomatis serotype L2. The DNA was isolated and fragmented by known methods, and the resulting DNA fragments were cloned into the plasmid PBR322 and transferred to the host organism Escherichia coli K12 HB101, by known methods. A gene bank of the Chlamydia trachomatis L2 bacterium was obtained as a result of the cloning, i.e. a large number of recombinant plasmids, each having a separate BamHI restriction fragment of DNA derived from chlamydiae. For reagent production, recombinant plasmids containing maximally large DNA inserts derived from chlamydial DNA were selected from the gene bank. One such plasmid is the one designed pKTH1220, which has been deposited at the culture collection Deutsche Sammlung von Microorganismen under the number (DSM 2825) and the suitability of which for use as a reagent was demonstrated by a direct hybridization test. The test showed that pKTH1220 identified all of the nucleic acids derived from different Chlamydia trachomatis

serotypes, but no other nucleic acids.

The applicable fragments, obtainable by using different restriction enzymes, were selected from the pKTH1220-plasmid DNA, and some of these fragments were transferred by further cloning into pAT153 plasmid (Maniatis et al., Molecular Cloning. A Laboratory Manual, Cold String Harbor Laboratory, p.6, 1982) and some to M13 phage. Fig. 10 shows the recombinant plasmid pKTH1220, having a molecular length of 14 kb. In Fig. 10, BamHI, Sall and Clal represent the restriction enzymes used, and a<sub>1</sub>, a<sub>2</sub>, b<sub>1</sub>, b<sub>2</sub> and b<sub>3</sub> illustrate the size and mutual locations of the fragments produced with the aid of these restriction enzymes. The fragments belonging to the series b as labeled probes. Table 1 lists the sizes of the fragments and the vectors used for further cloning, the names of the recombinant plasmids, and their use.

35 Table 1.

		Fragment	Size	Vector	Recombinant plasmid	Use	
40	a,	Clal-Sall	3.0kb	pAT153	pKTH1252	Filter	40
	a <sub>2</sub>	Sall-Clal	2.9kb	pAT153	pKTH1250	Filter	40
	b,	Sall-BamHl	0.7kb	M13mp8	mKTH1242	Labeled probe	
	b <sub>2</sub>	BamHI-Sall	1.4kb	M13mp8	mKTH1239	Labeled probe	
	b <sub>3</sub>	Clal-Clal	1.7kb	M13mp8	mKTH1248	Labeled probe	
45	b1-b2	BamHI-BamHI	2.1kb	M13mp8	mKTH1245	Labeled probe	45

The fragments listed in Table 1 were isolated from an agarose gel by electroelution and were cloned into the appropriate restriction enzyme identification sites of the vectors listed in Table 1, 50 by using known methods.

The fragment BamHI-BamHI 2.1kb was produced as follows: the fragments BamHI-Sall 1.4kb and Sall-BamHI 0.7kb of the plasmid pKTH1220 were separated by gel electrophoresis in agarose gel, from which they were isolated. The purified fragments were joined to each other with the aid of T4 ligase enzyme, and of the 2.1kb DNA fragments produced in the reaction, those which had free ends which were identified by the BamHI enzyme were further joined to the BamHI restriction site of the double-stranded form of the M13mp8 phage DNA. Thus there was made a recombinant phage-DNA (mKTH1245) which contains Chlamydia trachomatis DNA comprising two separate DNA fragments which are not located adjacently in the genome. However, in the genome they are located adjacent to the DNA reagents pKTH1250 and pKTH1252 to be affixed to the filter (Fig. 11). Fig. 11 shows an array of sandwich hybrids which is formed when the recombinant plasmids and recombinant phages listed in Table 1 are used as arrays of nucleic acid reagents.

(b) Demonstration of the sensitivity of an array of nucleic acid reagents from Chlamydia trachomatis by using the sandwich hybridization method

10

15

45

50

55

60

The hybridization was performed at +65°C for 17 hours in a hybridization solution having 10 the following composition: 4 × SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.2% SDS, and 200 µg/ml herring sperm DNA. The filters were washed for 2 h at 50°C with a washing solution, having the following composition: 0.1 imes SSC, 0.2% SDS, and were counted using a gamma-counter. The results are shown in Table 2 and are the means of five parallel tests.

#### Table 2.

50

20	Specimen	With	idized (b) a	radio	activity,		
25	molecules/test	ъ <sub>1</sub>	ъ <sub>2</sub>	b <sub>3</sub>	b <sub>1</sub> ,b <sub>2</sub>	(b <sub>1</sub> -b <sub>2</sub> )	(b <sub>1</sub> -b <sub>2</sub> ),b <sub>3</sub>
5	0 10 <sup>6</sup>	37 48	37 44	33 48	49	39	52
0	10 <sup>7</sup> 108	226 1475	236 1415	232 1456	93 396 2912	68 416 2637	140 686 3580

35 b <sub>1</sub> b <sub>2</sub> b <sub>3</sub> 40 b <sub>1</sub> -b <sub>2</sub> b <sub>1</sub> , b <sub>2</sub> (b <sub>1</sub> -b <sub>2</sub> ), b <sub>3</sub>	380,000 cpm/test; 5 x 10 <sup>7</sup> cpm/µgDNA 340,000 cpm/test; 4 x 107 cpm/µgDNA 350,000 cpm/test; 5 x 10 <sup>7</sup> cpm/µgDNA 310,000 cpm/test; 7 x 10 <sup>7</sup> cpm/µgDNA 700,000 cpm/test;	35 40
45		

Statistically calculated, the 95% confidence limit of the tests performed without a sample ( = negative controls) was regarded as the lower limit for positivity. These values were 52-54cpm when the probe was  $b_1$ ,  $b_2$  or  $b_3$ , 58 cpm when the probe was  $b_1$ ,  $b_2$ , 56 cpm when the probe was  $b_1-b_2$ , and 65 cpm when the probe was  $b_1-b_2$ ,  $b_3$ .

(c) Chlamydia diagnostics by using sandwich hybridization with arrays of nucleic acid frag-

Specimens taken from three men suffering from urethritis and three women suffering from cervicitis were selected for the test. Chlamydia trachomatis had been isolated from the male 55 urethral specimens and the female specimens taken from the cervix. In addition, a corresponding number of similar patient specimens, from which chlamydia had not been isolated, were studied. The specimens to be examined were taken with cotton-tipped swabs which were immersed in a chlamydia sample-taking buffer containing 0.2 M saccharrose, 20 mM phosphate buffer, 3% fetal calf serum, 10  $\mu$ g/ml gentamicin, 100  $\mu$ g/ml vancomycin, and 25 IU/ml 60 nystatin.

Chlamydia was cultivated from the specimens. The original specimens were also assayed by sandwich hybridization using an array of nucleic acid fragments. The specimens were concentrated by using 2-butanol to remove liquid from them in such a way that the final volume was about 80 µl, their concentration for the testing thus half a

treated for 15 min at 55°C and for 45 min at 37°C. Thereafter the specimen was boiled for 5 min in 0.175 M NaOH. The boiled specimen was transferred to 0°C and neutralized with an equimolar amount of acetic acid and tested. The filters and hybridization conditions described in Example 1b were used in the test. The probe used was mKTH1245 (b<sub>1</sub>-b<sub>2</sub>), 300,000 cpm/400 5 μl hybridization reaction. The results are shown in Table 3.

Table 3.

, 0					
	Specimen	Hybridized	Result of		10
		radioactivity	chlamydia	culture	
15	<del></del>				15
	Man 1.	151	+		13
	Man 2.	164	* +		
20	Man 3.	154	+		
	Man 4.	61	-		20
	Man 5.	76	· <b>_</b>		
	Man 6.	55	_		
25					25
	Woman 1.	343	+		
	Woman 2.	509	· +		
30	Woman 3.	362	+	·	
	Woman 4.	57	<del>-</del>		30
	Woman 5.	58	_	· ·	
35	Woman 6.	81	-		35
	Buffer, $\overline{X}_4$	30-55			33
40	Chl. trachomatis	419	+		40
45	The limit for positivity in The result in Table 3 sho fragments is suitable for di culture tests were negative	ows that sandwich hybragonsis venereal disease	ridization using	s which were nonething in all	45
50	Example 2. (a) An array of nucleic ac DNA fragments suitable	id reagents from Cyton for the diagnostics of C	negalovirus and	their preparation	50
55	EcoRI fragment I of about isolated from agarose gel be separated on the basis of the was precipitated with ethar pBR325 plasmid vector op	9 kb, defined in Spectory electroelution after the heir size. The eluted Direction The DNA thus purioned by using the Economic Processing Proce	as isolated and or et al., J. Viro he EcoRI restric NA was extracte fied was joined	fragmented by known methods.  I. 42, 558-582, 1982, was tion fragments had been ed with phenol, whereafter it by means of T4-ligase to the	55
	resistent but chloramphenic cytomegalovirus-specific DI virus DNA was ascertained kb EcoRI-DNA fragment was included in its HindIII-	col sensitive clones the NA insert of the correct by the Southern blot ras derived from the DI 1-D fragment (Orange).	pacteria. From a re was selected t size. The chara method. This tes NA of Cytomega	among ampicillin and tetracyclin one which contained a acter of the cloned cytomegalost ensured that the described 9 alovirus and, more specifically,	60
65	recombinant plasmid thus of	described was designat	ed pKTH 1271	, and it was deposited at the	65

10

25

30

35

culture collection Deutsche Sammlung von Microorganismen under number DSM 2826. The recombinant plasmid was grown and purified by known techniques.

The further clonings were carried out by known techniques by using as vectors the pBR322 plasmid and the M13mp7 and M13mp8 phages. Figs. 12 shows the hybrid plasmid in Fig. 12 were prepared by using the restriction enzymes EcoRI, BamHI, Clal and PstI. Fig. 12 location. Table 4 lists the sizes of the fragments in question and the vectors used for the further reagents or as labeled probes. Fig. 13 shows an array of sandwich hybrids which is formed when the array of nucleic acid fragments listed in Table 4 are used.

Table 4.

15	Restriction	fragment	Vector	Designation	use	
20 b <sub>2</sub> b <sub>3</sub>	EcoRI-Pstl Clal-BamHI Pstl-Pstl Pstl-Clal BamHO-EcoRI	(3.3kb) (3.0kb) (0.6kb) (1.0kb) (1.0kb)	pBR322 pBR322 M13mp7 M13mp8 M13mp8	pKTH1273 pKTF1274 mKTH1277 mKTH1278 mKTH1279	Filter Filter Labeled probe Labeled probe Labeled probe	15

(b) Demonstration of the sensitivity of an array nucleic acid reagents from cytomegalovirus by the sandwich hybridization method

The sensitivity of an array of nucleic acid reagents as compared with one continuous reagent pair was assayed by the sandwich hybridization method. The specimen in the tests was CMV DNA, which was boild in 0.17 M NaOH for 5 min. and was thereafter neutralized as in example 1b. Filters which all contained 101 molecules of both pKTH1273(a<sub>1</sub>) DNA and pKTH1274(a<sub>2</sub>) DNA, rendered single-stranded, and the following probes labeled with 125 Listed in Table 4.

30 DNA, rendered single-stranded, and the following probes labeled with  $^{125}$ J listed in Table 4: mKTH1277(b<sub>1</sub>), mKTH1278(b<sub>2</sub>) and mKTH1279(b<sub>3</sub>) were used in the test. The probes each results are shown in Table 5.

	<del></del>			:					
40	Specimen	Hybridized radioactivity, with (b) as the probe						40	
	molecules/test	ь1	b <sub>2</sub>	ъз	b <sub>1</sub> ,b <sub>2</sub>	b <sub>1</sub> ,b <sub>2</sub> ,b <sub>3</sub>			
45	0	35	33	38	45	53			45

	•							
	100		33	38	45	53	,	45
	4x10 <sup>6</sup>	38	44	46	95	125		
50	1.6x10 <sup>7</sup>	85	135	142	. 205	292		
	1.6x10	203	254	265	415	645		50

55	ы	310.000 cpm/test	
	b2	320.000 cpm/test	55
	b3	300.000 cpm/test	
60		300.000 cpm of each/test	
		300.000 cpm of each/test	60

15

20

25

30

50

55

60

65

5	or b <sub>3</sub> , 59 cpm when the probe was b <sub>1</sub> , b <sub>2</sub> , and 63 cpm when the probe was b <sub>1</sub> , b <sub>2</sub> , b <sub>3</sub> . The results in Table 5 show that sandwich hybridization in which an individual probe reagen in used (b <sub>1</sub> , b <sub>2</sub> or b <sub>3</sub> ) detects in each case 4 × 10 <sup>6</sup> CMV—DNA molecules. On the other hand, hybridization with a reagent of b <sub>1</sub> , b <sub>2</sub> or b <sub>1</sub> , b <sub>2</sub> , b <sub>3</sub> detects as few as 10 <sup>6</sup> molecules of CMV-DNA. The results show that the array of nucleic acid reagents are four times as sensitive as individual nucleic acid reagents.	

(c) CMV diagnostics by using sandwich hybridization with an array of nucleic acid reagents Clinical specimens were assayed by using sandwich hybridization with an array of reagents. 10 These samples included two urine specimens from children under 1 year. These children were suspected of suffering from congenital cytomegalo disease. A lung biopsy specimen from a patient with CMV pulmonary infection was also assayed by the present sandwich hybridization. Both cytomegalovirus-infected and uninfected human fetal cells were also used as specimens in

15 A solution which contained 1% sarcosyl and 5 mA EDTA and 200 μg calf thymus DNA was added to a 10 ml urine specimen, whereafter the DNA released from the virus, together with the carrier, was precipitated using 10 ml isopropanol at room temperature. The DNA precipitate was dissolved in 200  $\mu$ l of TE buffer and was brought to a single-stranded form by boiling it for 5 min, whereafter the DNA solution was cooled to 0°C and added to the hybridization solution. 20

The lung biopsy specimen (a few mm $^3$ ) was minced mechanically, with a knife, 200  $\mu$ l of TE buffer containing 1% SDS solution and 1 mg/ml of proteinase K-enzyme was added to it. A digestion was carried out at + 37°C for 1 h whereafter the specimen was drawn into an injection syringe twice through a thin hypodermical needle. The specimen thus homogenized was boiled, whereafter it was added to the test solution.

The cells infected with cytomegalovirus and the uninfected cells were broken up by an SDS, 25 proteinase K treatment, homogenized and boiled, as above.

The reagents in the hybridization test were pKTH1273(a1) and pKTH1274(a2) on filters and mKTH1277( $b_1$ ), mKTH1278( $b_2$ ), mKTH1279( $b_3$ ) as probes, each 200.000 cpm/reaction. In other respects the hybridization, the washing of the filters and the counting of the results were 30 carried out as described in Example 1b.

The results of the present hybridization are shown in Table 6.

Table 6.

35	Specimen	Hybridized radioactivity	Virus isolation	35
40	Infected cells (10 <sup>5</sup> ) Urine 1(10 ml) Urine 2(10 ml) Urine from a healthy	3521 : 243 3215	Not done CMV CMV	40
45	person (10 ml) Lung biopsy specimen Control cells 10 <sup>5</sup> No specimen	52 535 68 65	Not done CMV Not done Not done	45

The results in Table 6 show that it is possible, by using an array of nucleic acid reagents, to demonstrate CMV in different clinical specimens such as urine, lung biopsy specimens and cells. The test is specific to cytomegalovirus; it does not identify human DNA, i.e. the test is not 50 interfered by the human DNA present in the sample. In fact the type of specimen does not interfere with the specifity of test in any way.

#### CLAIMS

- 1. Nucleic acid reagents, characterized in that they comprise arrays of alternating nucleic acid fragments.
- 2. Nucleic acid reagents according to claim 1, characterized in that they comprise two or more series of at least two but preferably more arrays of alternating nucleic acid fragments sufficiently homologous to the nucleic acid which is to be identified but not homologous to one 60 another.
  - Nucleic acid reagents according to claims 1 and 2, characterized in that they comprise either separate or joined arrays of alternating nucleic acid fragments.
- 4. Nucleic acid reagents according to claims 1, 2 or 3 characterized in that they comprise arrays of nucleic acid fragments which either have or do not have vector-derived parts.
- 5. Nucleic acid reagents according to claim 1, 2, 3 or 4 characterized in that they comprise

40

A nucleic acid reagent as claimed in claim 1 and substantially as hereinbefore described. Printed in the United Kingdom for Her Majesty's Stationery Office. Dd 8818935, 1985, 4235.

Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

#### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

De	efects in the images include but are not limited to the items checked:
	☐ BLACK BORDERS
	☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
	☐ FADED TEXT OR DRAWING
	☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
	☐ SKEWED/SLANTED IMAGES
	☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
	☐ GRAY SCALE DOCUMENTS
ند	☐ LINES OR MARKS ON ORIGINAL DOCUMENT
	☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

#### IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER: \_\_\_\_

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.